Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 19/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054657 | 1.00 | KCNQ2 (0.67) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL30795547 | 0.93 | KCNQ2 (0.77) | KCNQ2KCNQ3 | |
| SCHEMBL1078477 | 0.93 | KCNQ2 (0.77) | KCNQ2KCNQ3 | |
| SCHEMBL12926928 | 0.90 | KCNQ2 (0.71) | KCNQ2KCNQ3L3MBTL1 | |
| SCHEMBL30795894 | 0.90 | KCNQ2 (0.71) | KCNQ2KCNQ3 | |
| SCHEMBL1000993 | 0.90 | KCNQ2 (0.71) | KCNQ2KCNQ3 | |
| SCHEMBL30814177 | 0.88 | KCNQ2 (0.87) | KCNQ2KCNQ3 | |
| SCHEMBL1003007 | 0.88 | KCNQ2 (0.87) | KCNQ2KCNQ3 | |
| SCHEMBL1001954 | 0.88 | KCNQ2 (0.80) | KCNQ2KCNQ3 | |
| SCHEMBL30794663 | 0.88 | KCNQ2 (0.80) | KCNQ2KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |